查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591792

血液腫瘤檢測市場：按產品和服務、癌症、技術、最終用戶分類 - 全球預測 2025-2030

Hemato Oncology Testing Market by Products & Services (Assay Kits, Services), Cancer (Leukemia, Non-Hodgkin Lymphoma), Technology, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

血液腫瘤檢測市場2023年估值為37.6億美元，預計到2024年將達到43.6億美元，複合年成長率為16.12%，到2030年將達到107.1億美元。

血液腫瘤學檢測包括對白血病、淋巴瘤和骨髓瘤等血癌的檢測和管理至關重要的診斷和監測程序。血液腫瘤學檢測的範圍包括多種技術，例如基因檢測、流式細胞技術、免疫化學和全血細胞計數檢測。這些方法在個人化醫療中發揮重要作用，可以實現改善患者治療效果的客製化治療。血液腫瘤檢測的需求源自於早期檢測、準確的預後預測和有效的治療監測的可能性。研究應用包括醫院、門診手術中心和診斷實驗室，最終用途集中在醫療機構、研究機構和生物技術公司。推動市場成長的主要因素是血癌盛行率的增加、基於基因組的診斷的進步以及對個人化醫療的認知不斷增強。次世代定序和液態切片等最新技術創新為提高診斷準確性和縮短週轉時間提供了商機。然而，高昂的測試成本、有限的保險報銷框架以及嚴格的監管要求等因素為市場拓展帶來了重大挑戰。為了克服這些障礙，公司需要專注於具有成本效益的解決方案，並瞄準醫療基礎設施投資不斷增加的新興市場。研究和創新可能會在非侵入性檢測技術、用於預測分析的人工智慧以及用於簡化資料共用和患者管理的數位健康工具整合等領域蓬勃發展。市場競爭需要持續創新，研究機構、醫療保健提供者和科技公司之間的合作培育了一個能夠帶來突破性進展的生態系統。總體而言，血液腫瘤學檢測前景廣闊，但公司必須策略性地解決財務限制和監管障礙，並利用科學進步和跨部門夥伴關係來擴大業務成長並提高患者照護標準。

主要市場統計
基準年[2023] 37.6億美元
預測年份 [2024] 43.6億美元
預測年份 [2030] 107.1億美元
複合年成長率（%） 16.12%

市場動態：快速發展的血液腫瘤檢測市場的關鍵市場洞察

供需的動態交互作用正在改變血液腫瘤學檢測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球血癌盛行率不斷上升
    • 消費者對個人化醫療的意識不斷增強
    • 隨著夥伴關係關係的擴大，新檢測方法的快速開發
  • 市場限制因素
    • 缺乏標準的報銷政策
  • 市場機會
    • 全球對先進治療方案的需求不斷成長
    • 不斷研發推出新的測試方法
  • 市場挑戰
    • 由於複雜的法律規範導致測試核准延遲

波特五力：駕馭血液腫瘤檢測市場的策略工具

波特的「五力」框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血液腫瘤檢測市場的外部影響

外部宏觀環境因素在塑造血液腫瘤檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解血液腫瘤檢測市場的競爭狀況

血液腫瘤測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，使他們的公司能夠應對日益激烈的競爭。

FPNV 定位矩陣血液腫瘤檢測市場供應商的績效評估

FPNV 定位矩陣是評估血液腫瘤檢測市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了血液腫瘤檢測市場的成功之路

血液腫瘤檢測市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球血癌發生率上升
      • 消費者對個人化醫療越來越了解
      • 擴大夥伴關係以快速開發新的檢測方法
    • 抑制因素
      • 缺乏標準退費政策
    • 機會
      • 全球對先進治療方法的需求不斷成長
      • 持續研究和開發引入新的測試程序
    • 任務
      • 複雜的法規結構延遲了測試核准
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章血液腫瘤檢測市場（依產品及服務）

  • 檢測試劑套件
  • 服務

第7章血液腫瘤檢測市場癌症

  • 白血病
  • 非何傑金氏淋巴瘤

第8章血液腫瘤檢測市場：依技術分類

  • 國際衛生
  • 下一代種子
  • PCR

第9章血液腫瘤測試市場：依最終用戶分類

  • 臨床實驗室
  • 醫院

第10章北美和南美血液腫瘤檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區血液腫瘤檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲血液腫瘤檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Boule Diagnostics AB
  • Danaher Corporation
  • Diatron Medical Instruments Limited
  • EKF Diagnostics Holdings PLC
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • Icon PLC
  • Illumina, Inc.
  • Mindray Bio-Medical Electronics Co., Ltd.
  • Nihon Kohden Corporation
  • Sanofi SA
Product Code: MRR-437E9896A58A

The Hemato Oncology Testing Market was valued at USD 3.76 billion in 2023, expected to reach USD 4.36 billion in 2024, and is projected to grow at a CAGR of 16.12%, to USD 10.71 billion by 2030.

Hemato oncology testing involves diagnostic and monitoring procedures essential for detecting and managing blood cancers such as leukemia, lymphoma, and myeloma. The scope of hemato oncology testing encompasses various techniques, including genetic testing, flow cytometry, immunochemistry, and complete blood count tests. These methods play a crucial role in personalized medicine, enabling tailored treatments that improve patient outcomes. The necessity for hemato oncology testing arises from its potential to offer early detection, precise prognosis, and effective treatment monitoring. Applications extend to hospitals, ambulatory surgical centers, and diagnostic laboratories, with end-use scope centered around healthcare institutions, research academies, and biotech firms. Market growth is primarily driven by an increasing prevalence of blood cancers, advancements in genome-based diagnostics, and heightened awareness of personalized medicine. Recent technological innovations, such as next-generation sequencing and liquid biopsy, offer lucrative opportunities for businesses to enhance diagnostic accuracy and reduce turnaround times. However, factors such as high testing costs, limited reimbursement frameworks, and stringent regulatory requirements pose significant challenges to market expansion. To overcome these obstacles, companies need to focus on cost-effective solutions and target emerging markets where investment in healthcare infrastructure is rising. Research and innovation can thrive in areas like non-invasive testing technologies, artificial intelligence for predictive analytics, and integration of digital health tools for streamlined data sharing and patient management. The competitive nature of the market requires continuous innovation, with collaboration among research entities, healthcare providers, and technology firms fostering an ecosystem conducive to groundbreaking advancements. Overall, hemato oncology testing holds promising prospects, but businesses must strategically address financial constraints and regulatory hurdles, leveraging scientific advancements and cross-sector partnerships to drive business growth and enhance patient care standards.

KEY MARKET STATISTICS
Base Year [2023] USD 3.76 billion
Estimated Year [2024] USD 4.36 billion
Forecast Year [2030] USD 10.71 billion
CAGR (%) 16.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemato Oncology Testing Market

The Hemato Oncology Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of hematologic cancer globally
    • Rising awareness on personalized medicine among consumers
    • Rapid development of new assays with growing partnerships
  • Market Restraints
    • Lack of standard reimbursement policies
  • Market Opportunities
    • Emerging demand for advanced treatment options globally
    • Ongoing research and development for the introduction of new testing procedures
  • Market Challenges
    • Complicated regulatory framework results in delayed approval of tests

Porter's Five Forces: A Strategic Tool for Navigating the Hemato Oncology Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemato Oncology Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemato Oncology Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemato Oncology Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemato Oncology Testing Market

A detailed market share analysis in the Hemato Oncology Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemato Oncology Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemato Oncology Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemato Oncology Testing Market

A strategic analysis of the Hemato Oncology Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemato Oncology Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Boule Diagnostics AB, Danaher Corporation, Diatron Medical Instruments Limited, EKF Diagnostics Holdings PLC, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Icon PLC, Illumina, Inc., Mindray Bio-Medical Electronics Co., Ltd., Nihon Kohden Corporation, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Hemato Oncology Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products & Services, market is studied across Assay Kits and Services.
  • Based on Cancer, market is studied across Leukemia and Non-Hodgkin Lymphoma.
  • Based on Technology, market is studied across IHC, NGS, and PCR.
  • Based on End-User, market is studied across Clinical Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of hematologic cancer globally
      • 5.1.1.2. Rising awareness on personalized medicine among consumers
      • 5.1.1.3. Rapid development of new assays with growing partnerships
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of standard reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging demand for advanced treatment options globally
      • 5.1.3.2. Ongoing research and development for the introduction of new testing procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Complicated regulatory framework results in delayed approval of tests
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemato Oncology Testing Market, by Products & Services

  • 6.1. Introduction
  • 6.2. Assay Kits
  • 6.3. Services

7. Hemato Oncology Testing Market, by Cancer

  • 7.1. Introduction
  • 7.2. Leukemia
  • 7.3. Non-Hodgkin Lymphoma

8. Hemato Oncology Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. IHC
  • 8.3. NGS
  • 8.4. PCR

9. Hemato Oncology Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinical Laboratories
  • 9.3. Hospitals

10. Americas Hemato Oncology Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hemato Oncology Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hemato Oncology Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adaptive Biotechnologies Corporation
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Boule Diagnostics AB
  • 5. Danaher Corporation
  • 6. Diatron Medical Instruments Limited
  • 7. EKF Diagnostics Holdings PLC
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. HORIBA, Ltd.
  • 10. Icon PLC
  • 11. Illumina, Inc.
  • 12. Mindray Bio-Medical Electronics Co., Ltd.
  • 13. Nihon Kohden Corporation
  • 14. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. HEMATO ONCOLOGY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HEMATO ONCOLOGY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMATO ONCOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMATO ONCOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMATO ONCOLOGY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMATO ONCOLOGY TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY IHC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY NGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. HEMATO ONCOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. HEMATO ONCOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2023